CLC bio and VIB Agree on an Academic Regional Site License

CLC bio and VIB Agree on an Academic Regional Site License

GHENT, Belgium & AARHUS, Denmark, Feb 09, 2012 (BUSINESS WIRE) -- Today, CLC bio and VIB, a life sciences research institute in Flanders, Belgium, announced the signing of an academic regional site license agreement for CLC bio's sequence analysis software CLC DNA Workbench. The software will be used across academic institutions in the Flanders region in Belgium, including Universiteit Gent, Katholieke Universiteit Leuven, University of Antwerp, and the Vrije Universiteit Brussel.

Herwig Van Marck, Manager of BITS, the facility that manages a portfolio of up-to-date bioinformatics software for scientists at VIB, states, "Bioinformatics is central to almost all areas of life sciences research today, so our researchers need access to the best and most innovative tools. When CLC bio added multisite gateway cloning to their suite, it was a straightforward decision to select this package for sequence data analysis."

Director of Communications at CLC bio, Lasse Gorlitz, continues, "With the whole life science field moving rapidly towards adopting DNA sequence analysis for a wide range of purposes, this is an important investment in biomolecular research for both the Flanders region and all of Belgium. VIB selecting to provide their researchers and students with access to cutting-edge and user-friendly bioinformatics tools, emphasizes VIB's commitment to spearheading life science research!"

VIB is a life sciences research institute in Belgium with more than 1200 scientists from over 60 countries, working in close partnership with Universiteit Gent, Katholieke Universiteit Leuven, University of Antwerp, and the Vrije Universiteit Brussel.

CLC bio is the world's leading bioinformatics solution provider and the only one who provides both desktop and server software seamlessly integrated and optimized for best performance. CLC bio maintains a strong scientific focus by initializing and participating in various research projects around the world, including multiple projects funded by US and EU grants.

About VIB

http://www.vib.be

About CLC bio

http://www.clcbio.com/about

SOURCE: Clc bio

 

       
        Contact VIB
        Herwig Van Marck
        Phone: +32 9 244 66 11
        E-mail: [email protected]
        Contact CLC bio
        Lasse Gorlitz
        Director of Communications
        Phone: +1 (617) 765 0687
        E-mail: [email protected]

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.